{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:27:18Z","timestamp":1780097238840,"version":"3.54.0"},"reference-count":15,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory multiple myeloma (RRMM) frequently develop drug resistance, leading to poor survival outcomes. Zevorcabtagene autoleucel (zevor-cel or CT053) is a fully human B-cell maturation antigen, targeting chimeric antigen receptor (CAR) T-cell therapy for patients with RRMM. The phase 1 part of LUMMICAR study 1 was a single-arm, open-label, multi-center study conducted in China, enrolling patients with RRMM who received \u22653 prior regimens. Safety, tolerability, efficacy, and pharmacokinetics were evaluated. Fourteen patients (50% male) received single infusion of zevor-cel (100 \u00d7 106 [n = 3] and 150 \u00d7 106 CAR T cells [n = 11]). As of 22 February 2025, with the median follow-up duration of 53.3 months (range, 14.8-63.5), 13 (92.9%) patients experienced grade 1 or 2 cytokine release syndrome. No immune effector cell\u2013associated neurotoxicity syndrome, delayed neurotoxicities, second primary malignancy, or other delayed adverse events were observed. There were 3 deaths, and none were zevor-cel\u2013related. The objective response rate was 100% (95% confidence interval [CI], 76.8-100.0) and 11 (78.6%) patients achieved complete response or better, 13 (92.9%) with very good partial response or better response and 1 (7.1%) with partial response. The median duration of response was 24.94 months (95% CI, 14.03-45.86). The proportion of patients with a response lasting \u226536 months and \u226548 months were 41.7% and 15.6%, respectively. At 24, 36, 48, and 60 months after infusion, overall survival rates were 100%, 92.3%, 84.6%, and 76.9%, respectively. This 53.3-month median follow-up data of zevor-cel reaffirms the initial results with a manageable safety profile and compelling efficacy in RRMM. This trial was registered at www.clinicaltrials.gov (NCT03975907).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017365","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:02:06Z","timestamp":1761768126000},"page":"468-478","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Long-term follow-up of zevor-cel in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"given":"Chengcheng","family":"Fu","sequence":"first","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[{"name":"3Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Yan","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Shang","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-8612","authenticated-orcid":false,"given":"Yin","family":"Wu","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yan","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-8960","authenticated-orcid":false,"given":"Xiaolan","family":"Shi","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Han","sequence":"additional","affiliation":[{"name":"3Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Tang","sequence":"additional","affiliation":[{"name":"1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Zheng","sequence":"additional","affiliation":[{"name":"3Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Wen","sequence":"additional","affiliation":[{"name":"3Multiple Myeloma Center, Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Meng","sequence":"additional","affiliation":[{"name":"4CARsgen Therapeutics Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijing","family":"Yuan","sequence":"additional","affiliation":[{"name":"4CARsgen Therapeutics Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamao","family":"Wang","sequence":"additional","affiliation":[{"name":"4CARsgen Therapeutics Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghai","family":"Li","sequence":"additional","affiliation":[{"name":"4CARsgen Therapeutics Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"1","key":"2026012709520069500_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2026012709520069500_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2026012709520069500_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"2026012709520069500_bib4","unstructured":"U.S. Food & Drug Administration\n          . FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma. Accessed 6 June 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma."},{"key":"2026012709520069500_bib5","unstructured":"U.S. Food & Drug Administration\n          . FDA Approves Idecabtagene Vicleucel for Multiple Myeloma. Accessed 6 June 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"key":"2026012709520069500_bib6","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"2026012709520069500_bib7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","article-title":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 16","key":"2026012709520069500_bib8","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2023.41.16_suppl.8010","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: at least 5-year follow-up in LEGEND-2","volume":"41","author":"Mi","year":"2023","journal-title":"JCO"},{"issue":"suppl 1","key":"2026012709520069500_bib9","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year follow-up on efficacy and safety results from phase 1 Lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026012709520069500_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"2026012709520069500_bib11","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"10297","key":"2026012709520069500_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"2026012709520069500_bib13","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026012709520069500_bib14","doi-asserted-by":"crossref","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"2026012709520069500_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/468\/2498492\/blooda_adv-2025-017365-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/468\/2498492\/blooda_adv-2025-017365-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:52:10Z","timestamp":1769525530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/468\/547972\/Long-term-follow-up-of-zevor-cel-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017365","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,16]]}}}